Intellia Therapeutics NTLA Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -651.7%+271pp | -923.1%+426pp | -1,349.2%-470pp | -879%-68.7pp | |
| Net margin | -609.9%+287pp | -896.8%+363pp | -1,259.9%-350pp | -909.8%-99.3pp | |
| EBITDA margin | -637.2%+268pp | -905.3%+420pp | -1,325.7%-461pp | -864.5%-75.0pp | |
| Free cash flow margin | -585%+27.8pp | -612.8%+456pp | -1,068.5%-403pp | -665.5%+53.9pp | |
| Returns | |||||
| Return on equity | -53.5%+0.5pp | -54%-11.9pp | -42.1%-0.4pp | -41.7%-7.5pp | |
| Return on assets | -40.6%+1.1pp | -41.7%-7.5pp | -34.1%-0.4pp | -33.7%-6.5pp | |
| Return on invested capital | -58.7%-0.4pp | -58.3%-0.5pp | -57.8%-7.9pp | -50%-11.6pp | |
| Efficiency | |||||
| Asset turnover | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | |||||
| Current ratio | 5.1×-0.7× | 5.8×-2.9× | 8.7×-0.9× | 9.6×+3.5× | |
| Quick ratio | 5.1×-0.7× | 5.8×-2.9× | 8.7×-0.9× | 9.6×+3.5× | |
| Cash ratio | 1.5×-0.2× | 1.7×-0.3× | 2×-2.2× | 4.1×+3.2× | |
| Leverage | |||||
| Debt-to-equity | 0.1×-0.1× | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.1×-0.1× | 0.2×+0.1× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | |||||
| Book value per share | $6.20-29.8% | $8.82-25.4% | $11.83-26.3% | $16.05+9.4% | |
| Valuation | |||||
| Market capitalization | $1.04B-12.3% | $1.19B-56.9% | $2.76B-7.3% | $2.97B-66.2% | |
| Enterprise value | $979.18M-19.0% | $1.21B-54.3% | $2.65B+2.5% | $2.58B-70.5% | |
| Price / sales | 15.4×-5.1× | 20.5×-51.7× | 72.2×+15.2× | 57.1×-209× | |
| Price / book | 1.6×+0.2× | 1.4×-1.3× | 2.6×+0.2× | 2.4×-6.1× | |
| EV / sales | 14.5×-6.4× | 20.9×-48.4× | 69.3×+19.8× | 49.5×-215× | |
| Free cash flow yield | -38%-8.2pp | -29.9%-15.1pp | -14.8%-3.1pp | -11.7%-9.0pp | |
| Earnings yield | -39.6%+4.1pp | -43.7%-26.3pp | -17.4%-1.5pp | -15.9%-12.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Intellia Therapeutics's ratios come from?
- Every ratio is computed from Intellia Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.